Clinical trials: Poor Graft Function
Poor Graft Function
Decitabine for Poor Graft Function Post Allo-HSCT
This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.
- Trial name
- NCT05907499
- Testing
- Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist
- Where
- China
- Volunteers
- 76 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Poor Graft Function
Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function
The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks…
- Trial name
- ELTION (NCT03718533)
- Testing
- Eltrombopag
- Where
- 7 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Hematopoietic Stem Cell Transplant, Poor Marrow Graft Function
T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy.
- Trial name
- NCT02350777
- Testing
- Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion, CliniMACS Cell Selection System
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center